To broadly assess the functional outcome of over-expressing SIVA-WT and SIVA-D160N compared to control (EV) across multiple cell lines, additional stable polyclonal transfectants of these expression vectors were achieved in human breast cancer (HCC-1954) and ovarian cancer (SKOV3 and OVCAR8) cell lines. The gene discussed is SIVA1; the disease is ovarian carcinoma.